Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$4.26 - $6.51 $2,130 - $3,255
-500 Reduced 5.43%
8,700 $45,000
Q3 2023

Oct 26, 2023

BUY
$15.21 - $22.88 $139,932 - $210,496
9,200 New
9,200 $145,000
Q2 2022

Jul 25, 2022

SELL
$41.26 - $51.35 $264,064 - $328,640
-6,400 Reduced 68.82%
2,900 $128,000
Q1 2022

Apr 21, 2022

BUY
$44.58 - $52.6 $414,594 - $489,180
9,300 New
9,300 $460,000
Q4 2020

Jan 25, 2021

SELL
$41.72 - $51.34 $66,752 - $82,144
-1,600 Closed
0 $0
Q3 2020

Dec 14, 2020

SELL
$37.02 - $51.28 $392,412 - $543,568
-10,600 Reduced 86.89%
1,600 $67,000
Q2 2020

Jul 23, 2020

BUY
$43.24 - $55.02 $17,296 - $22,008
400 Added 3.39%
12,200 $585,000
Q1 2020

Apr 23, 2020

BUY
$34.37 - $60.07 $13,747 - $24,028
400 Added 3.51%
11,800 $542,000
Q4 2019

Jan 24, 2020

SELL
$54.32 - $64.31 $10,864 - $12,862
-200 Reduced 1.72%
11,400 $684,000
Q3 2019

Oct 21, 2019

SELL
$53.25 - $59.98 $42,600 - $47,984
-800 Reduced 6.45%
11,600 $656,000
Q2 2019

Jul 25, 2019

BUY
$46.61 - $58.45 $23,305 - $29,225
500 Added 4.2%
12,400 $690,000
Q2 2018

Aug 06, 2018

BUY
$51.25 - $76.62 $507,375 - $758,538
9,900 Added 495.0%
11,900 $900,000
Q1 2018

Apr 20, 2018

SELL
$52.16 - $66.86 $20,864 - $26,744
-400 Reduced 16.67%
2,000 $105,000
Q4 2017

Jan 23, 2018

SELL
$49.6 - $60.87 $500,960 - $614,787
-10,100 Reduced 80.8%
2,400 $128,000
Q3 2017

Oct 23, 2017

BUY
$46.62 - $60.36 $582,750 - $754,500
12,500
12,500 $745,000

Others Institutions Holding EGRX

About EAGLE PHARMACEUTICALS, INC.


  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $7.81M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Strs Ohio Portfolio

Follow Strs Ohio and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.